Friedlander 2018.

Study characteristics
Methods	A randomised, double‐blind, placebo‐controlled trial
Participants	107 (55 pregabalin, 52 placebo) Women initiating medical abortion with mifepristone and buccal misoprostol up to 70 days of gestation
Interventions	Participants were randomised to 300 mg oral pregabalin or a placebo immediately before misoprostol.
Outcomes	Pain score, GI side effects, satisfaction with analgesia, satisfaction with abortion
Notes	Trial registration: NCT02782169 (prospective) Dates: June 2015–October 2016 Funding: Society of Family Planning Research Fund, Grant Award Number SFPRF15‐12 Conflicts of Interest: Dr. Soon receives research support from Contramed Pharmaceuticals, Merck Sharpe and Dohme, Mithra Pharmaceuticals, and Gynuity Health Projects. Dr. Tschann receives research support from Contramed Pharmaceuticals, Merck Sharpe and Dohme, Mithra Pharmaceuticals, Gynuity Health Projects, and the National Institutes of Health. Dr. Kaneshiro receives research support from Contramed Pharmaceuticals, Merck Sharpe and Dohme, Mithra Pharmaceuticals, Gynuity Health Projects, and the National Institutes of Health. She is also a consultant for UpToDate. All of these sources of outside research support did not play any role in this project’s study design, data collection, analysis, interpretation writing of the report, or decision to submit the report for publication. The other authors did not report any potential conflicts of interest.  Contact attempted to gather missing data – no further data provided